Delaware-based pharmaceutical company AstraZeneca is currently testing a drug that has potential to treat Alzheimer’s disease. Many potential Alzheimer’s treatments right now are targeting the abnormal growth of two types of proteins in the brains affected by the disease. These are beta-amyloids and tau proteins, which are also known as “plaques” and “tangles,” respectively.
The drug, called AZD3293, was produced by AstraZeneca’s Neuroscience iMed group in partnership with Eli Lilly. AZD3293 works by blocking the beta-secretase or BACE enzyme, that produces these plaques. AstraZeneca began developing the drug in 1999, shortly after the discovery of the BACE enzyme.